EQL Pharma AB (publ)

OM:EQL Rapporto sulle azioni

Cap. di mercato: SEK 2.0b

EQL Pharma Gestione

Gestione criteri di controllo 3/4

EQL Pharma Il CEO è Axel Schorling, nominato in Aug2022, e ha un mandato di 2.25 anni. la retribuzione annua totale è SEK 2.26M, composta da 72.6% di stipendio e 27.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.07% delle azioni della società, per un valore di SEK 21.58M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.3 anni e 4.8 anni.

Informazioni chiave

Axel Schorling

Amministratore delegato

SEK 2.3m

Compenso totale

Percentuale dello stipendio del CEO72.6%
Mandato del CEO2.3yrs
Proprietà del CEO1.1%
Durata media del management2.3yrs
Durata media del Consiglio di amministrazione4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Nov 27
Should You Be Adding EQL Pharma (STO:EQL) To Your Watchlist Today?

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29
Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13
EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14
EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21
EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Jun 28
The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Apr 28
With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Feb 24
EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Dec 19
EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Jun 29
Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

Apr 29
Is EQL Pharma (NGM:EQL) Using Too Much Debt?

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Aug 10
We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Jun 07
EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

Apr 16
If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11
How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03
Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16
What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11
What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22
EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Axel Schorling rispetto agli utili di EQL Pharma?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

SEK 31m

Jun 30 2024n/an/a

SEK 26m

Mar 31 2024SEK 2mSEK 2m

SEK 23m

Compensazione vs Mercato: La retribuzione totale di Axel ($USD 205.64K ) è inferiore alla media delle aziende di dimensioni simili nel mercato Swedish ($USD 467.92K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Axel con le performance aziendali.


AMMINISTRATORE DELEGATO

Axel Schorling (38 yo)

2.3yrs

Mandato

SEK 2,262,000

Compensazione

Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Christer Fahraeus
Founder & Chairman18.8yrsSEK 250.00kNessun dato
Axel Schorling
President & CEO2.3yrsSEK 2.26m1.07%
SEK 21.6m
Anna Jonsson
Chief Financial Officer2.9yrsNessun dato0.047%
SEK 952.8k
Martin Kristofferson
Chief Operating Officer2.3yrsNessun dato0.070%
SEK 1.4m
Alexander Brising
Chief Commercial Officerno dataNessun dato0.88%
SEK 17.8m
Carl Lindgren
Chief Business Development Officer1.7yrsNessun datoNessun dato

2.3yrs

Durata media

50yo

Età media

Gestione esperta: Il team dirigenziale di EQL è considerato esperto (durata media dell'incarico 2.3 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Christer Fahraeus
Founder & Chairman18.8yrsSEK 250.00kNessun dato
Linda Neckmar
Independent Director4.8yrsSEK 100.00k0.0086%
SEK 173.5k
Anders Mansson
Independent Director6.3yrsSEK 100.00k0.034%
SEK 694.1k
Per Svangren
Independent Director3.8yrsSEK 100.00k0.034%
SEK 694.1k
Per Ollermark
Independent Director3.8yrsSEK 100.00kNessun dato

4.8yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di EQL sono considerati esperti (durata media dell'incarico 4.8 anni).